Study S000526

Improved Treatment and Monitoring of Alzheimer's Disease - a Randomized Controlled Clinical Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07135245
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 180
Start: 2026-01-01
Primary completion: 2030-09-30
Lead sponsor: Rune Skovgaard Rasmussen
Conditions: Alzheimer Disease (AD)
Interventions: DRUG:Semaglutide (Rybelsus®) combined with other interventions; OTHER:Placebo; DRUG:Semaglutide (Rybelsus®)
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

The Montreal Cognitive Assessment [At inclusion, and 52 and 78 weeks.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.